Zydus Cadila to be US$ 3 billion company by 2015: Company Officials

Subscribe to GoodReturns

Zydus Cadila to be US$ 3 billion company by 2015
Zydus Cadila, which is one of the leading pharma Company, is aiming to become a US$ 3 billion company by 2015 end. By the end of FY 2011, the company"s consolidated revenues reached approximately Rs. 4,630 crore in comparison to Rs. 3,687 crore revenues in FY 2010, representing a YoY growth of almost 26 per cent. According to company"s spokesman, “After having entered the billion dollar league our next aim is to be a three billion USD company by 2015."

Zydus Cadila is listed on the stock exchange as Cadila Healthcare. 

In order to achieve this target, the company has entered into new segments like biosimilars. Foray into this new segment has helped the company to receive the marketing authorisation of biosimilar version of Erythropoietin (EPO) in the Indian market in FY 2011. EPO is very useful in the treatment of anaemia and in special cases where the blood count of the patient goes down.

According to a company statement, "The Company has completed clinical trials of biosimilar versions of Teriparatide, which is meant for treatment of osteoporosis, and PEG-IFNa-2b, used for treating chronic hepatitis infections."

In addition to this, Zydus has also got the permission and approval from US-FDA for conduction clinical trials of ZYGK1 (glucokinase activator) to lower blood glucose and IND-ZYD1 which is used for the treatment of diabetes.

Read more about: cadila healthcare, pharma, bse, nse, investment
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?